GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shandong Buchang Pharmaceuticals Co 603858.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

14.98

-0.79%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥11.88bn

FY2016FY2025

Net income

CN¥360.8m

FY2016FY2025

Free cash flow

CN¥1.03bn

FY2016FY2025

Shareholders' equity

CN¥10.01bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥11.88bnCN¥11.01bnCN¥13.25bnCN¥14.95bnCN¥15.76bnCN¥16.01bnCN¥14.26bnCN¥13.66bnCN¥13.86bnCN¥12.32bn
Gross profitCN¥7.48bnCN¥6.45bnCN¥8.92bnCN¥10.68bnCN¥11.63bnCN¥12.27bnCN¥11.87bnCN¥11.31bnCN¥11.41bnCN¥10.24bn
Research and developmentCN¥240.1mCN¥486.0mCN¥335.1mCN¥284.1mCN¥408.6mCN¥533.4mCN¥505.4mCN¥480.2mCN¥489.4mCN¥458.9m
Operating incomeCN¥649.3m−CN¥242.3mCN¥436.0mCN¥1.78bnCN¥1.75bnCN¥2.37bnCN¥2.43bnCN¥2.27bnCN¥1.81bnCN¥2.02bn
Net incomeCN¥360.8m−CN¥553.8mCN¥319.0m−CN¥1.53bnCN¥1.29bnCN¥1.86bnCN¥1.95bnCN¥1.89bnCN¥1.64bnCN¥1.77bn
Diluted earnings per share0.34-0.520.29-1.381.171.681.751.651.421.71

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥19.24bnCN¥19.33bnCN¥20.89bnCN¥21.95bnCN¥23.99bnCN¥22.89bnCN¥21.19bnCN¥20.03bnCN¥19.20bnCN¥18.67bn
Cash and short-term investments—CN¥1.22bnCN¥1.05bnCN¥2.88bnCN¥1.72bnCN¥1.86bnCN¥2.22bnCN¥1.69bnCN¥2.17bnCN¥3.81bn
Total liabilitiesCN¥9.81bnCN¥9.52bnCN¥9.52bnCN¥9.68bnCN¥9.54bnCN¥9.08bnCN¥7.40bnCN¥6.17bnCN¥5.98bnCN¥5.96bn
DebtCN¥2.13bnCN¥2.47bnCN¥2.35bnCN¥3.15bnCN¥3.54bnCN¥3.45bnCN¥2.72bnCN¥2.25bnCN¥1.80bnCN¥6.0m
Shareholders' equityCN¥10.01bnCN¥10.22bnCN¥11.62bnCN¥12.36bnCN¥14.42bnCN¥13.71bnCN¥13.64bnCN¥13.73bnCN¥13.14bnCN¥12.61bn
Shares outstanding1,055m1,061m1,106m1,106m1,106m1,106m1,110m1,141m1,152m1,034m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.16bnCN¥940.0m−CN¥164.3mCN¥2.76bnCN¥1.32bnCN¥1.96bnCN¥2.62bnCN¥2.05bnCN¥1.96bnCN¥1.67bn
Capital spending−CN¥123.4m−CN¥197.0m−CN¥529.9m−CN¥543.2m−CN¥433.5m−CN¥536.4m−CN¥662.1m−CN¥1.31bn−CN¥1.46bn−CN¥677.9m
Free cash flowCN¥1.03bnCN¥743.0m−CN¥694.2mCN¥2.21bnCN¥887.0mCN¥1.42bnCN¥1.96bnCN¥741.0mCN¥506.9mCN¥990.9m
Dividends paid−CN¥530.7m−CN¥272.4m−CN¥1.19bn−CN¥398.2m−CN¥581.8m−CN¥1.79bn−CN¥1.37bn−CN¥1.19bn−CN¥1.17bn−CN¥137.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥2.42bnCN¥2.58bnCN¥3.41bnCN¥2.80bnCN¥2.88bnCN¥2.78bnCN¥2.49bnCN¥3.08bn
Gross profitCN¥1.43bnCN¥1.63bnCN¥2.20bnCN¥1.74bnCN¥1.81bnCN¥1.72bnCN¥1.59bnCN¥1.79bn
Operating incomeCN¥281.7mCN¥440.2mCN¥384.0mCN¥278.6mCN¥384.9mCN¥382.8m−CN¥25.5mCN¥215.8m
Net incomeCN¥182.2mCN¥320.4m−CN¥507.5mCN¥240.6mCN¥320.4mCN¥307.3m−CN¥866.7mCN¥81.4m
Diluted earnings per share0.170.30-0.480.230.300.29-0.820.08
Cash from operations———−CN¥145.0mCN¥280.0mCN¥679.0mCN¥246.0mCN¥203.0m
Capital spending−CN¥70.0m−CN¥16.0m−CN¥37.0m−CN¥22.0m−CN¥25.0m−CN¥37.0m−CN¥8.0m−CN¥54.0m
Free cash flow———−CN¥167.0mCN¥255.0mCN¥642.0mCN¥238.0mCN¥149.0m
Total assetsCN¥19.16bnCN¥19.64bnCN¥19.24bnCN¥19.57bnCN¥19.98bnCN¥19.84bnCN¥19.33bnCN¥20.15bn
Cash and short-term investments———CN¥1.56bnCN¥2.24bnCN¥2.14bnCN¥1.22bnCN¥1.31bn
DebtCN¥2.58bnCN¥2.53bnCN¥2.13bnCN¥1.68bnCN¥2.47bnCN¥2.64bnCN¥2.47bnCN¥3.03bn
Shareholders' equityCN¥10.06bnCN¥10.22bnCN¥10.01bnCN¥10.57bnCN¥10.74bnCN¥10.48bnCN¥10.22bnCN¥11.16bn

Financial ratios

Data as of 29 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin62.9%58.6%67.4%71.5%73.8%76.6%
Operating margin5.5%-2.2%3.3%11.9%11.1%14.8%
Net margin3.0%-5.0%2.4%-10.2%8.2%11.6%
Return on equity3.6%-5.4%2.7%-12.4%8.9%13.6%
Return on assets1.9%-2.9%1.5%-7.0%5.4%8.1%
Free cash flow yield8.4%7.4%2.3%20.6%11.0%15.6%
Revenue growth7.9%-16.9%-11.4%-5.1%-1.5%12.3%
Earnings growth-165.1%-273.6%-120.9%-218.7%-30.7%-4.4%
Current ratio1.10x1.06x1.21x1.29x1.17x1.02x
Debt to equity0.21x0.24x0.20x0.22x0.24x0.25x
Equity ratio52.0%52.9%55.6%56.3%60.1%59.9%
Interest coverage5.50x-1.79x3.97x12.50x10.45x16.31x
R&D as a share of sales2.0%4.4%2.5%1.9%2.6%3.3%
Buybacks as a share of market value0.6%4.1%0.0%0.0%-0.0%0.3%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-7.4%-5.8%0.2%
Operating income-28.5%-22.8%-16.1%
Net income—-28.0%-20.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin60.9%65.7%69.3%75.3%
Operating margin1.8%5.1%8.1%12.8%
Net margin-0.8%-2.7%2.1%8.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings45.7-30.359.0-15.218.113.711.811.821.233.0
Price to sales1.41.51.41.61.51.61.61.62.54.7

Dividends and splits

Per share, in the currency the company pays

Paid for 9 years. Last went ex-dividend on 26 Sept 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year0.390.1260.960.360.5261.6141.2420.955
  • 13-for-10 split · 19 Aug 2019
  • 13-for-10 split · 17 Aug 2018

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.